| Abstrakt: |
"In some embodiments, the recombinant ACE2 polypeptide, the fusion protein, and/or the composition as described above has increased efficacy in neutralizing SARS-CoV-2 virus compared to wild-type human ACE2 protein ectodomain. "In some embodiments, the recombinant ACE2 polypeptide, the fusion protein, and/or the composition as described above has increased binding affinity for SARS-CoV-2 spike RBD relative to wild-type human ACE2 protein ectodomain. The recombinant ACE2 polypeptide of claim 31, wherein the recombinant ACE2 polypeptide has greater than 25-fold higher neutralization efficacy for SARS-CoV-2 virus compared to wild-type human ACE2 protein ectodomain. "In some embodiments, the recombinant ACE2 polypeptide, the fusion protein, and/or the composition as described above has greater than 25-fold higher neutralization efficacy for SARS-CoV-2 virus compared to wild-type human ACE2 protein ectodomain.". [Extracted from the article] |
